Transactions
19
Insider / VERTEX PHARMACEUTICALS INC / MA
Lagarde Michel
Director at VERTEX PHARMACEUTICALS INC / MA
- First filing on record
- November 14, 2025
- Latest trade on record
- May 1, 2026
- SEC filings
- EDGAR ↗
Lagarde Michel, Director at VERTEX PHARMACEUTICALS INC / MA, has disclosed 19 transactions in VRTX, TMO since November 14, 2025: 0 purchases (0 open-market buys) and 7 sales, worth about $68.9M at the reported prices. The latest was filed May 5, 2026, 4 days after the trade.
Open-market buys
0
Sales
7
Avg. disclosure lag
1.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Lagarde Michel made no purchases and 7 sales worth $52M, plus 12 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Lagarde Michel has traded 1 stock on record; the largest by dollars is TMO.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 10 | 298,642 | $17.0M |
| S | Open-market sale | 5 | 88,684 | $51.3M |
| A | Grant or award | 2 | 5,097 | — |
| F | Shares withheld for tax | 2 | 1,197 | $624K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 4 | 0 | 2 · $624K |
| 2025 | 15 | 0 | 5 · $51.3M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | Other A | May 1, 2026 | May 5, 2026 | 4d | 2,866 | — | — | derivative | Form 4 ↗ | |
| TMO | Sell F | February 28, 2026 | March 2, 2026 | 2d | 360 | $521 | $187K | Form 4 ↗ | ||
| TMO | Sell F | February 28, 2026 | March 2, 2026 | 2d | 837 | $521 | $436K | Form 4 ↗ | ||
| TMO | Other A | February 25, 2026 | February 27, 2026 | 2d | 2,231 | — | — | Form 4 ↗ | ||
| TMO | Option / conversion M | December 4, 2025 | December 5, 2025 | 1d | 18,637 | — | — | derivative | Form 4 ↗ | |
| TMO | Option / conversion M | December 4, 2025 | December 5, 2025 | 1d | 22,046 | — | — | derivative | Form 4 ↗ | |
| TMO | Sell S | December 4, 2025 | December 5, 2025 | 1d | 22,046 | $564 | $12.4M | Form 4 ↗ | ||
| TMO | Option / conversion M | December 4, 2025 | December 5, 2025 | 1d | 22,046 | $133 | $2.9M | Form 4 ↗ | ||
| TMO | Option / conversion M | December 4, 2025 | December 5, 2025 | 1d | 18,637 | $105 | $2.0M | Form 4 ↗ | ||
| TMO | Option / conversion M | December 3, 2025 | December 4, 2025 | 1d | 68,000 | — | — | derivative | Form 4 ↗ | |
| TMO | Option / conversion M | December 2, 2025 | December 4, 2025 | 2d | 36,000 | — | — | derivative | Form 4 ↗ | |
| TMO | Sell S | December 3, 2025 | December 4, 2025 | 1d | 2,521 | $584 | $1.5M | Form 4 ↗ | ||
| TMO | Sell S | December 3, 2025 | December 4, 2025 | 1d | 29,479 | $583 | $17.2M | Form 4 ↗ | ||
| TMO | Option / conversion M | December 3, 2025 | December 4, 2025 | 1d | 68,000 | $105 | $7.2M | Form 4 ↗ | ||
| TMO | Sell S | December 2, 2025 | December 4, 2025 | 2d | 30,000 | $582 | $17.5M | Form 4 ↗ | ||
| TMO | Option / conversion M | December 2, 2025 | December 4, 2025 | 2d | 36,000 | $105 | $3.8M | Form 4 ↗ | ||
| TMO | Option / conversion M | November 13, 2025 | November 14, 2025 | 1d | 4,638 | — | — | derivative | Form 4 ↗ | |
| TMO | Sell S | November 13, 2025 | November 14, 2025 | 1d | 4,638 | $594 | $2.8M | Form 4 ↗ | ||
| TMO | Option / conversion M | November 13, 2025 | November 14, 2025 | 1d | 4,638 | $254 | $1.2M | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 5, 2026 | Form 4 | 0000875320-26-000181 | 1 | published | EDGAR ↗ |
| March 2, 2026 | Form 4 | 0000097745-26-000047 | 2 | published | EDGAR ↗ |
| February 27, 2026 | Form 4 | 0000097745-26-000036 | 1 | published | EDGAR ↗ |
| December 5, 2025 | Form 4 | 0000097745-25-000180 | 5 | published | EDGAR ↗ |
| December 4, 2025 | Form 4 | 0000097745-25-000178 | 7 | published | EDGAR ↗ |
| November 14, 2025 | Form 4 | 0000097745-25-000166 | 3 | published | EDGAR ↗ |
Other insiders at VERTEX PHARMACEUTICALS INC / MA
- CASPER MARC N Chairman & CEO 163 rows
- LEIDEN JEFFREY M Executive Chairman 31 rows
- Pettiti Gianluca President & COO 24 rows
- Shafer Michael D Executive Vice President 23 rows
- Sachdev Amit EVP Chief Patient & Ext Af Off 21 rows
- Britt Lisa P. Sr. VP and Chief HR Officer 20 rows
- Kewalramani Reshma CEO & President 20 rows
- JOHNSON JENNIFER M Director 18 rows
- Lowery Frederick M. CEO 18 rows
- Bozic Carmen EVP and CMO 17 rows
Everyone on file, with contracts and lobbying under the company's name: VERTEX PHARMACEUTICALS INC / MA.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 19 | November 14, 2025 | May 5, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.